See more : GAON CABLE Co., Ltd. (000500.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Infinity Pharmaceuticals, Inc. (INFI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Infinity Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Asia Precision Public Company Limited (APCS.BK) Income Statement Analysis – Financial Results
- MPDL LIMITED (MPDL.BO) Income Statement Analysis – Financial Results
- Rapid Micro Biosystems, Inc. (RPID) Income Statement Analysis – Financial Results
- Sernova Corp. (SVA.TO) Income Statement Analysis – Financial Results
- Fiverr International Ltd. (FVRR) Income Statement Analysis – Financial Results
Infinity Pharmaceuticals, Inc. (INFI)
About Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.59M | 1.86M | 1.72M | 3.05M | 22.15M | 6.00M | 18.72M | 109.07M | 165.00M | 0.00 | 47.11M | 92.77M | 71.33M | 49.54M | 83.44M | 24.54M | 18.49M | 34.84M | 51.56M | 49.83M | 41.32M | 41.13M | 36.26M | 13.08M | 6.20M | 3.10M | 400.00K | 0.00 |
| Cost of Revenue | 1.56M | 1.12M | 1.04M | 7.31M | 69.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.11M | 29.44M | 31.67M | 35.49M | 24.86M | 9.90M | 7.87M | 2.80M | 1.30M | 200.00K | 0.00 |
| Gross Profit | 1.03M | 738.00K | 682.00K | -4.26M | 22.08M | 6.00M | 18.72M | 109.07M | 165.00M | 0.00 | 47.11M | 92.77M | 71.33M | 49.54M | 83.44M | 24.54M | 18.49M | 9.73M | 22.12M | 18.16M | 5.83M | 16.28M | 26.37M | 5.20M | 3.40M | 1.80M | 200.00K | 0.00 |
| Gross Profit Ratio | 39.72% | 39.72% | 39.67% | -139.69% | 99.69% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 27.93% | 42.91% | 36.44% | 14.10% | 39.57% | 72.71% | 39.78% | 54.84% | 58.06% | 50.00% | 0.00% |
| Research & Development | 32.41M | 31.65M | 26.76M | 27.12M | 19.76M | 20.83M | 119.61M | 199.11M | 143.63M | 99.76M | 118.60M | 108.58M | 99.23M | 77.86M | 47.47M | 33.79M | 35.79M | 3.92M | 4.30M | 2.55M | 6.22M | 12.98M | 8.93M | 3.54M | 5.10M | 4.10M | 2.60M | 600.00K |
| General & Administrative | 13.46M | 14.17M | 12.42M | 14.29M | 14.25M | 21.62M | 42.22M | 37.07M | 29.29M | 27.92M | 27.88M | 0.00 | 21.07M | 19.46M | 16.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.00M | 2.50M | 1.60M | 600.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.46M | 14.17M | 12.42M | 14.29M | 14.25M | 21.62M | 42.22M | 37.07M | 29.29M | 27.92M | 27.88M | 22.72M | 21.07M | 19.46M | 16.84M | 14.03M | 9.46M | 15.07M | 14.10M | 13.96M | 12.27M | 11.02M | 8.41M | 4.44M | 5.00M | 2.50M | 1.60M | 600.00K |
| Other Expenses | 1.56M | 1.12M | 1.04M | 7.31M | 69.00K | -6.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -100.00K | 100.00K | 0.00 | 0.00 |
| Operating Expenses | 45.87M | 45.82M | 39.18M | 41.41M | 34.01M | 42.45M | 161.83M | 236.17M | 172.92M | 127.68M | 146.28M | 131.30M | 120.30M | 97.31M | 64.30M | 47.83M | 45.26M | 24.72M | 19.41M | 17.03M | 70.21M | 30.92M | 30.55M | 8.65M | 10.00M | 6.70M | 4.20M | 1.20M |
| Cost & Expenses | 47.44M | 46.94M | 40.22M | 48.71M | 34.08M | 42.45M | 161.83M | 236.17M | 172.92M | 127.68M | 146.28M | 131.30M | 120.30M | 97.31M | 64.30M | 47.83M | 45.26M | 49.83M | 48.85M | 48.70M | 105.69M | 55.78M | 40.45M | 16.52M | 12.80M | 8.00M | 4.40M | 1.20M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 339.00K | 0.00 | 559.00K | 326.75K | 463.01K | 2.04M | 3.34M | 6.58M | 2.46M | 2.02M | 1.42M | 1.80M | 2.18M | 3.53M | 2.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 180.00K | 180.00K | 2.45M | 2.56M | 93.00K | 1.01M | 1.23M | 1.37M | 9.65M | 0.00 | 1.91M | 1.84M | 1.91M | 1.30M | 21.37K | 188.04K | 1.51M | 4.81K | 6.14K | 40.75K | 144.47K | 279.58K | 1.53M | 0.00 | 300.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 458.00K | 480.00K | 483.00K | 219.00K | 191.00K | 1.72M | 3.42M | 2.29M | 1.77M | 1.82M | 1.64M | 2.10M | 2.18M | 2.15M | 1.97M | 2.81M | 3.69M | 6.23M | 6.71M | 5.29M | 57.04M | 12.60M | 13.20M | 671.71K | 600.00K | 200.00K | 0.00 | 0.00 |
| EBITDA | -44.84M | -44.60M | -38.01M | -45.66M | -11.74M | -43.33M | -30.89M | -127.11M | -7.58M | -125.85M | -52.81M | -36.10M | -48.97B | -47.77B | 24.45M | -20.48M | -26.76B | -16.04B | 9.60M | 8.24M | -64.38B | -14.65B | 17.89M | -2.64M | -5.40M | -4.60M | -4.00M | -1.20M |
| EBITDA Ratio | -1,729.43% | -2,400.59% | -2,211.40% | -1,497.67% | -53.00% | -722.12% | -764.34% | -116.54% | -4.60% | 0.00% | -205.82% | -38.91% | -66.98% | -63.66% | 29.30% | -83.48% | -116.38% | -9.51% | 18.62% | 16.54% | 106.23% | -4.95% | 49.32% | -20.20% | -87.10% | -148.39% | -1,000.00% | 0.00% |
| Operating Income | -44.84M | -45.08M | -38.50M | -45.66M | -11.93M | -36.45M | -30.89M | -127.11M | -7.92M | -127.68M | -52.81M | -38.53M | -48.97M | -47.77M | 19.14M | -23.29M | -26.76M | -16.04M | 2.72M | -748.49K | -64.38M | -14.65M | -4.18M | -3.45M | -6.60M | -4.80M | -4.00M | -1.20M |
| Operating Income Ratio | -1,729.43% | -2,426.43% | -2,239.50% | -1,497.67% | -53.87% | -607.42% | -164.99% | -116.54% | -4.80% | 0.00% | -112.09% | -41.53% | -68.65% | -96.44% | 22.94% | -94.92% | -144.70% | -46.03% | 5.27% | -1.50% | -155.83% | -35.61% | -11.53% | -26.36% | -106.45% | -154.84% | -1,000.00% | 0.00% |
| Total Other Income/Expenses | 475.00K | -179.00K | -2.00M | -1.45M | 676.00K | -6.11M | 790.00K | -933.00K | -9.31M | 896.00K | -1.16M | -1.51M | -713.27K | 14.94M | 4.52M | 6.39M | -598.01K | 2.33M | 1.24M | -1.82M | -51.23M | 3.50B | -8.87M | -133.92K | 300.00K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -44.37M | -45.26M | -40.49M | -47.11M | -11.25M | -42.55M | -30.10M | -128.04M | -17.23M | -126.78M | -53.96M | -40.04M | -49.68M | -32.83M | 23.65M | -16.90M | -27.36M | -13.71M | 3.96M | -2.57M | -115.61M | -14.66M | -13.05M | -3.58M | -6.30M | -4.80M | -4.00M | -1.20M |
| Income Before Tax Ratio | -1,711.11% | -2,436.06% | -2,355.56% | -1,545.13% | -50.81% | -709.17% | -160.77% | -117.40% | -10.44% | 0.00% | -114.54% | -43.16% | -69.65% | -66.28% | 28.35% | -68.87% | -147.94% | -39.35% | 7.68% | -5.16% | -279.82% | -35.64% | -35.98% | -27.39% | -101.61% | -154.84% | -1,000.00% | 0.00% |
| Income Tax Expense | -1.11M | 180.00K | 2.45M | -54.00K | 769.00K | -720.00K | -2.19M | 335.00K | 183.00K | 0.00 | 1.91M | 326.75K | -700.32K | -329.57K | 21.37K | 0.00 | 1.09M | 13.24K | 55.58K | 65.59K | -2.27M | -3.50M | 7.51M | -76.72K | 600.00K | 0.00 | 0.00 | 0.00 |
| Net Income | -43.26M | -45.44M | -42.94M | -47.06M | -11.25M | -41.83M | -30.10M | -128.38M | -17.42M | -126.78M | -53.96M | -40.04M | -48.98M | -32.51M | 23.65M | -16.90M | -28.45M | -14.16M | 3.90M | 1.06M | -62.11M | -11.15M | -11.70M | -3.37M | -6.30M | -4.80M | -4.00M | -1.20M |
| Net Income Ratio | -1,668.18% | -2,445.75% | -2,497.79% | -1,543.36% | -50.81% | -697.17% | -160.77% | -117.70% | -10.56% | 0.00% | -114.54% | -43.16% | -68.67% | -65.62% | 28.35% | -68.87% | -153.82% | -40.66% | 7.57% | 2.13% | -150.34% | -27.10% | -32.25% | -25.78% | -101.61% | -154.84% | -1,000.00% | 0.00% |
| EPS | -0.48 | -0.53 | -0.72 | -0.83 | -0.20 | -0.83 | -0.61 | -2.62 | -0.36 | -2.64 | -1.70 | -1.50 | -1.86 | -1.24 | 1.17 | -0.87 | -3.81 | -6.62 | -18.72 | -26.33 | -71.98 | -1.86 | -3.55 | -11.98 | -31.50 | -48.00 | -40.00 | -0.01 |
| EPS Diluted | -0.48 | -0.53 | -0.72 | -0.83 | -0.20 | -0.83 | -0.61 | -2.62 | -0.36 | -2.64 | -1.70 | -1.50 | -1.86 | -1.24 | 1.14 | -0.87 | -3.81 | -6.62 | -18.72 | -26.33 | -71.98 | -1.86 | -3.55 | -11.98 | -31.50 | -48.00 | -40.00 | -0.01 |
| Weighted Avg Shares Out | 89.25M | 85.60M | 59.86M | 56.98M | 55.41M | 50.56M | 49.61M | 49.08M | 48.56M | 47.94M | 31.71M | 26.62M | 26.32M | 26.20M | 20.24M | 19.51M | 7.46M | 2.14M | 1.82M | 1.29M | 862.93K | 6.00M | 3.29M | 281.26K | 200.00K | 100.00K | 100.00K | 89.02M |
| Weighted Avg Shares Out (Dil) | 89.25M | 85.60M | 59.86M | 56.98M | 55.41M | 50.56M | 49.61M | 49.08M | 48.56M | 47.94M | 31.71M | 26.62M | 26.32M | 26.20M | 20.77M | 19.51M | 7.46M | 2.14M | 6.54M | 6.08M | 862.93K | 6.00M | 3.29M | 281.26K | 200.00K | 100.00K | 100.00K | 89.02M |
INFI DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 16 Deadline in Securities Class Action – INFI
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (OTC: INFIQ) between January 5, 2022 and July 24, 2023, both dates inclusive (the “Class Period”), of the...
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 16, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of §§10(b)...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of 10(b)...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of §§10(b)...
FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 10, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of §§10(b)...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Infinity Pharmaceuticals, Inc. - INFI
NEW YORK , Oct. 9, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company") (NASDAQ: INFI). Such investors are advised to contact Robert S.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of §§10(b)...
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of 10(b)...
INFI IMPORTANT DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 16 Deadline in Securities Class Action - INFI
NEW YORK , Oct. 5, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) between January 5, 2022 and July 24, 2023, both dates inclusive (the "Class...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of §§10(b)...
Source: https://incomestatements.info
Category: Stock Reports